Indication
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Medicine details
- Medicine name:
- trastuzumab deruxtecan (Enhertu)
- SMC ID:
- SMC2608
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 11 December 2023
- SMC meeting date:
- 07 November 2023
- Patient group submission deadline:
- 04 September 2023